ORLANDO, Fla. Pier Paolo Pandolfi, M.D., Ph.D., is the recipient of the 2011 Pezcoller Foundation-AACR International Award for Cancer Research for his outstanding work in the field of cancer genetics and mouse models for cancer. This work has contributed to new therapies for treating cancers.
"Dr. Pandolfi's research has had a profound impact on our understanding of the molecular underpinnings of acute promyelocytic leukemia (APL)," said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. "His laboratory's mouse models for various subtypes of APL have shown efficacy when utilizing different drug combinations. Clearly, this innovative research is leading to progress in the treatment of other types of cancer."
Pandolfi is the George C. Reisman Professor of Medicine and a professor of pathology at Harvard Medical School; director of research at the Beth Israel Deaconess Cancer Center; and director of the cancer genetics program and chief of the division of genetics in the department of medicine at the Beth Israel Deaconess Medical Center. His studies have had an impact on the cancer research arena by broadening the understanding of the molecular basis of cancer.
The research carried out in Pandolfi's laboratory has been important in understanding the molecular mechanisms and genetics underlying the pathogenesis of leukemias, lymphomas and solid tumors, as well as in modeling these cancers in mice.
Among his many accomplishments, Pandolfi and colleagues have characterized the function of oncoproteins and genes involved in the chromosomal translocations of APL, as well as of major tumor suppressors such as PTEN and p53, and novel proto-oncogenes, such as POKEMON. These accomplishments have led to the development of novel and effective therapeutic strategies, and, as a result, APL is now considered a curable disease.
Additional novel therapeutic concepts have emerged from Pandolfi's research, which are curr
|Contact: Michele Sharp|
American Association for Cancer Research